Médecine

Paramédical

Autres domaines


S'abonner

Comparison of perfused volume segmentation between cone-beam CT and 99mTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using 90Y-glass microspheres - 23/12/20

Doi : 10.1016/j.diii.2020.09.003 
M. Martin a, , A. Hocquelet b, F. Debordeaux c, L. Bordenave c, d, J.-F. Blanc e, P. Papadopoulos a, B. Lapuyade a, H. Trillaud a, f, J.-B. Pinaquy c
a Department of Radiology, CHU de Bordeaux, CIC1401, 33000 Bordeaux, France 
b Department of Radiology, CHU Vaudois, 1011 Lausanne, Switzerland 
c Department of Nuclear Medicine, CHU de Bordeaux, CIC1401, 33000 Bordeaux, France 
d Université de Bordeaux, INSERM, Bioingénierie tissulaire, U1026, 33000 Bordeaux, France 
e Department of Gastroenterology-Hepatology, hôpital Haut-Lévêque, CHU de Bordeaux, 33000 Bordeaux, France 
f Univ. Bordeaux, Institut de mathématique, MONC, UMR 5251, 33000 Bordeaux, France 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Highlights

Cone-beam CT may be a reproductible and reliable method for perfused volume segmentation.
Cone-beam CT does not significantly increase accuracy of dose prediction by comparison with 99mTc-MAA SPECT/CT.
Cone-beam CT may be particularly appropriate if there are multiple injection sites or for radiation segmentectomy.

Le texte complet de cet article est disponible en PDF.

Abstract

Purpose

To compare the reliability and accuracy of the pre-treatment dosimetry predictions using cone-beam computed tomography (CBCT) versus 99mTc-labeled macroaggregated albumin (MAA) SPECT/CT for perfused volume segmentation in patients with hepatocellular carcinoma treated by selective internal radiation therapy (SIRT) using 90Y-glass microspheres.

Materials and methods

Fifteen patients (8 men, 7 women) with a mean age of 68.3±10.5 (SD) years (range: 47–82 years) who underwent a total of 17 SIRT procedures using 90Y-glass microspheres for unresectable hepatocellular carcinoma were retrospectively included. Pre-treatment dosimetry data were calculated from 99mTc-MAA SPECT/CT using either CBCT or 99mTc-MAA SPECT/CT to segment the perfused volumes. Post-treatment dosimetry data were calculated using 90Y imaging (SPECT/CT or PET/CT). The whole liver, non-tumoral liver, and tumor volumes were segmented on CT or MRI data. The mean absorbed doses of the tumor (DT), non-tumoral liver, perfused liver (DPL) and perfused non-tumoral liver were calculated. Intra- and interobserver reliabilities were investigated by calculating Lin's concordant correlation coefficients (ρc values). The differences (biases) between pre- and post-treatment dosimetry data were assessed using the modified Bland–Altman method (for non-normally distributed variables), and systematic bias was evaluated using Passing–Bablok regression.

Results

The intra- and interobserver reliabilities were good-to-excellent (ρc: 0.80–0.99) for all measures using both methods. Compared with 90Y imaging, the median differences were 5.8Gy (IQR: −12.7; 16.1) and 5.6Gy (IQR: −13.6; 10.2) for DPL-CBCT and DPL-99mTc-MAA SPECT/CT, respectively. The median differences were 1.6Gy (IQR: −29; 7.53) and 9.8Gy (IQR: −28.4; 19.9) for DT-CBCT and DT-99mTc-MAA SPECT/CT respectively. Passing–Bablok regression analysis showed that both CBCT and 99mTc-MAA SPECT/CT had proportional biases and thus tendencies to overestimate DT and DPL at higher post-treatment doses.

Conclusion

CBCT may be a reliable segmentation method, but it does not significantly increase the accuracy of dose prediction compared with that of 99mTc-MAA SPECT/CT. At higher doses both methods tend to overestimate the doses to tumors and perfused livers.

Le texte complet de cet article est disponible en PDF.

Keywords : Brachytherapy, Radiation dosimetry, Yttrium-90, Carcinoma, hepatocellular, Cone-beam CT, SPECT CT

Abbreviations : 90Y, 95% CI, 99mTc, BCLC, CBCT, CD-CTHA, CT, ICC, HCC, MAA, MELD, MIRD, MRI, PET, Q1, Q3, SIRT, SPECT/CT, SD, T/N, VOI


Plan


© 2020  Soci showét showé françaises de radiologie. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 102 - N° 1

P. 45-52 - janvier 2021 Retour au numéro
Article précédent Article précédent
  • Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria
  • M. Ghosn, H. Derbel, R. Kharrat, N. Oubaya, S. Mulé, J. Chalaye, H. Regnault, G. Amaddeo, E. Itti, A. Luciani, H. Kobeiter, V. Tacher
| Article suivant Article suivant
  • Percutaneous irreversible electroporation of porta hepatis lymph node metastasis
  • Julien Garnon, Pierre Auloge, Danoob Dalili, Roberto L. Cazzato, Afshin Gangi

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.